{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "TENX", "name": "Tenax Therapeutics, Inc.", "url": "https://frontierpicks.com/dossiers/TENX/", "json_url": "https://frontierpicks.com/dossiers/TENX.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Phase 3 binary resolved negative: LEVEL missed its primary (6MWD +3.5m, p=0.63) and key secondary on 2026-08-10; four desks cut within 24h and the target band went from $27–$50 to $4–$5. Narrative is dead. What is left is a balance-sheet question — $118.0M cash at 2026-06-30 against 31.9M shares — with no base formed and RSI(14) at 9.8.", "invalidation_trigger": "A weekly close below $1.55 breaks the post-failure capitulation zone and shows the balance-sheet bid failing; a Type C FDA outcome with no defined enriched-population registrational path, or an equity raise priced under $2, would confirm.", "catalyst_date": "2026-08-28", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "binary-catalyst-biotech", "precision-biotech-therapeutics" ], "tags": [], "sources": [], "notes": [ "Single-asset issuer: TNX-103 (oral levosimendan) carries essentially all pipeline value; there is no approved product or revenue line.", "Share count went from 9.3M (2025-12-31) to 31.9M (2026-06-30); the issuer has a history of dilutive raises and reverse splits.", "With the 2026-08-14 close at $1.80, the Nasdaq $1.00 minimum-bid rule is a live listing consideration on any further decline.", "The ESC late-breaker (Munich, 2026-08-28 to 08-31) presents data whose topline is already public; the new content is subgroup and hemodynamic granularity." ], "body_markdown": "## Current Thesis\nThe binary resolved, and it resolved against the drug. On 2026-08-10 Tenax reported that the Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF missed its primary endpoint — a least-squares mean difference in 6-minute walk distance of 3.5 metres versus placebo, p=0.63 — and also missed the key secondary, the KCCQ total symptom score. The stock is quoted at $1.80 (2026-08-14 close), 90.2% below the 52-week high of $18.32, with a three-month return of -85.0% and RSI(14) at 9.8.\n\nThe narrative leg is dead, and 2026-08-10 is the date that killed it. A correction to the earlier reading of this name belongs here: the June–July analyst cluster ($27–$50 price targets across Piper Sandler, Guggenheim, Chardan, Cantor, Evercore and Canaccord) was pre-data initiation, never post-data validation. Topline had not been released in June. Canaccord Genuity initiated Buy with a $35 target on 2026-07-28, thirteen days before the failure. Within roughly 24 hours of the print, Chardan cut to Neutral $5, Evercore ISI cut to In-Line $5, Guggenheim held Buy but cut its target to $4, and William Blair moved to Market Perform. A $27–$50 band became a $4–$5 band.\n\nWhat remains is a balance-sheet and optionality question, not a clinical one.\n\n## Bull Case\n- There is no immediate financing gun to the head.\n- INFERRED, from two disclosed numbers: 31.9 million shares outstanding at 2026-06-30, at the 2026-08-14 close of $1.80, implies an equity value below the quarter-end cash figure. That gap narrows every quarter the company burns — Q2 net loss was $17.8 million.\n- The drug is pharmacologically active even where the endpoint failed: a 49% placebo-adjusted reduction in NT-proBNP and a 3.5 mmHg reduction in right ventricular systolic pressure across the overall population (2026-08-10 topline release), with a prespecified subgroup of higher-disease-burden patients showing a treatment effect. The company itself characterised these as not establishing efficacy.\n- Management has said it plans a Type C FDA meeting to discuss an enriched patient population and revisions to the registrational programme. A defined path would convert a dead single-asset story into a smaller, slower one.\n- The ESC Congress 2026 late-breaker (Munich, 2026-08-28 to 08-31, presented by Prof. Sanjiv Shah, Northwestern) puts the full dataset in front of cardiologists rather than leaving the market with a press release.\n\n## Bear Case\n- p=0.63 on a 3.5-metre walk-distance difference across 241 patients at 41 US and Canadian sites is a flat curve, not a narrow miss. Nothing about that number invites a re-run of the same design.\n- The key secondary (KCCQ-TSS) missed as well, so there is no symptom-benefit fallback to pair with the biomarker data.\n- Post-hoc and prespecified subgroup rescue after a null primary is a weak regulatory hand; the company's own language conceded the exploratory analyses do not establish efficacy.\n- LEVEL-2, the second pivotal trial, was guided at the 2026-07-31 update to complete enrollment by end-2027. Continuing it burns $118.0 million against a failed first pivotal; killing it removes the remaining clinical asset. Both branches are bad for the equity story.\n- Dilution has already run hard: 9.3 million shares at 2025-12-31 became 31.9 million at 2026-06-30.\n- At $1.80 the Nasdaq $1.00 minimum-bid rule is within reach of a further decline, and this issuer has used reverse splits before.\n\n## Setup & Price Structure\nThe June breakout shelf near $18 referenced in the prior note was destroyed in a single session on 2026-08-10 and is now distant overhead supply, not support. Price sits below every short- and intermediate-term moving average, all of which are rolling over. RSI(14) at 9.8 on 2026-08-14 is a measured extreme — the kind of reading that produces violent bounces without producing bases. Four sessions of post-event trade is not a sample from which a bottom can be identified.\n\nOn crowding and positioning, the observables: seven sell-side desks were published on the name into the print, the last initiation landing thirteen days before it; four of them repriced within 24 hours to $4–$5 targets or a withdrawn buy rating; the share count more than tripled in six months, meaning issuance into strength already happened ahead of the failure; and the only structural anchor left is a cash figure that is a quarter stale. The distribution was done by the desks and by the warrant holders, in that order.\n\nThe $118.0 million cash line creates a soft floor in arithmetic only. It is not a claim on assets, it funds a programme whose lead indication just failed, and $17.8 million of quarterly net loss erodes it.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-28 to 2026-08-31** — ESC Congress 2026, Munich. Late-Breaking Clinical Science presentation of full LEVEL data, \"Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial,\" Prof. Sanjiv Shah (announced 2026-07-02, reaffirmed 2026-07-31). Topline is already public, so the new information is subgroup granularity, hemodynamic detail and the reaction of cardiology KOLs in the room.\n- **~2026-Q4 (est., no date announced)** — Type C FDA meeting on an enriched population and registrational revisions. Outside the 30-day window; no scheduled date has been disclosed.\n- **~2026-11 (est.)** — Q3 2026 results and 10-Q, the first disclosure of the post-failure spending plan and whether LEVEL-2 continues.\n\n## What Would Change Our Mind\nThe read flips constructive only on evidence, not on a bounce. Specifically: full ESC data on 2026-08-28 to 08-31 showing separation in the prespecified higher-disease-burden subgroup with confidence intervals a regulator could work with; or an 8-K disclosing a Type C outcome in which FDA accepts a defined enriched-population registrational design; or a decision to halt LEVEL-2 and return capital or pursue a strategic transaction, which would make the $118.0 million cash line a real anchor rather than a burn schedule.\n\nOn the downside, the residual balance-sheet read breaks on a weekly close below $1.55, which would put price under the post-failure capitulation zone and show that bid failing four weeks after the event. An equity raise priced under $2, or a Nasdaq minimum-bid deficiency letter, would confirm the break. If instead the ESC session passes on 2026-08-31 with no incremental disclosure and price is unchanged, the catalyst calendar is empty until November — a name with no dated event, a failed lead asset and a shrinking cash pile has nothing left to price off.\n\n## Correlation Notes\nBeta to small-cap biotech risk appetite (XBI) is now secondary; the tape is idiosyncratic and event-driven. LEVEL is a randomised, 241-patient test of the inodilator hypothesis in PH-HFpEF, and its failure is an external negative datapoint for other sponsors targeting that population — the read-across runs from Tenax outward, not inward. Within the failed-readout cohort, the relevant comparison set is post-Phase-3 micro-caps trading near or below disclosed cash, where the subsequent path is usually determined by a board decision on wind-down versus continuation rather than by sector flows. Analyst-target dispersion has collapsed from an ~85% spread ($27–$50) to a tight $4–$5 cluster, so the sell-side is no longer a source of differentiated flow in this name.", "first_seen": "2026-07-07", "last_analyzed": "2026-08-16T16:29:33+00:00", "last_synthesized": "2026-08-16", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }